Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The proposed study is a double-blind, placebo-controlled, cross over study on 60 children
aged 5 to 25 years with severe spasticity related to cerebral palsy (CP), level IV and V with
full-spectrum medical cannabis product of CBD/THC ratio 10:1.
Phase:
N/A
Details
Lead Sponsor:
University Medical Centre Ljubljana
Collaborators:
PharmaHemp University of Ljubljana, Faculty of Medicine